β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.
about
Doping in sport: effects, harm and misconceptions.Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.Dietary supplementation and doping-related factors in high-level sailing.RNA interference for performance enhancement and detection in doping control.Acute impact of inhaled short acting b2-agonists on 5 km running performance.The impact of exercise-induced bronchoconstriction on athletic performance: a systematic review.Doping in sport and exercise: anabolic, ergogenic, health and clinical issues.β-Adrenergic modulation of skeletal muscle contraction: key role of excitation-contraction coupling.Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport.Combined inhalation of beta2 -agonists improves swim ergometer sprint performance but not high-intensity swim performance.The Effect of 400 µg Inhaled Salbutamol on 3 km Time Trial Performance in a Low Humidity Environment.Asthma medication is increasingly prescribed for finnish olympic athletes--for a reason?Salbutamol effects on systemic potassium dynamics during and following intense continuous and intermittent exercise.Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic β2-adrenergic stimulation in men.Effects of acute and 2-week administration of oral salbutamol on exercise performance and muscle strength in athletes.Two-week inhalation of budesonide increases muscle Na,K ATPase content but not endurance in response to terbutaline in men.Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance.Futility of current urine salbutamol doping control.
P2860
Q34446275-2732F9A9-3964-4263-98FC-E58FC3A177D8Q36424867-DAC1E85B-9CDC-43B0-B11B-7DD5BE33782CQ36507460-CF2C5713-B174-42B7-9FFA-721BE2B19825Q37949928-9DC96345-EE25-430A-9957-D25D531353DFQ38208815-CC98F1DD-3C35-4A09-86C9-81FDCB64BE5AQ38240496-D021B43E-27E7-4015-B353-117547F565F4Q38589015-6D4BC2BD-598D-4FD1-93DB-F4471B78102AQ38591913-9F2442E0-8B0D-4428-AD42-7301707F9F1AQ38736611-6348F755-31C3-47F2-89BB-09A3D45B8BC1Q39389063-D015196A-9B2B-4962-B980-AC3D6B8EABCCQ47104589-D9FDFBA6-28ED-4C50-A40F-001AB5B5ED9DQ47290992-9426DD61-874E-4E33-BF1C-4D89F5FFF2A8Q47374059-3F9DF228-AD96-425D-A35B-C9AD07E93159Q48160423-B093A718-AFFC-4DED-8EBC-5157AFC94401Q50247086-1D491D54-2846-4B0D-B770-F59AA319382DQ51533869-7DDA61E9-2D5F-48BD-9792-2C45A7841AEAQ51695203-DAABA12F-B560-40EA-A949-474D24BA4C40Q55654382-3866EFB7-BB08-4E51-AD99-AF64640CEB33
P2860
β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
β₂-Agonists and physical perfo ...... randomized controlled trials.
@ast
β₂-Agonists and physical perfo ...... randomized controlled trials.
@en
β₂-Agonists and physical perfo ...... randomized controlled trials.
@nl
type
label
β₂-Agonists and physical perfo ...... randomized controlled trials.
@ast
β₂-Agonists and physical perfo ...... randomized controlled trials.
@en
β₂-Agonists and physical perfo ...... randomized controlled trials.
@nl
prefLabel
β₂-Agonists and physical perfo ...... randomized controlled trials.
@ast
β₂-Agonists and physical perfo ...... randomized controlled trials.
@en
β₂-Agonists and physical perfo ...... randomized controlled trials.
@nl
P2093
P2860
P31
P1433
P1476
β₂-Agonists and physical perfo ...... f randomized controlled trials
@en
P2093
Aeilko H Zwinderman
Babette M Pluim
Harm Kuipers
Olivier de Hon
Rob J P M Scholten
Shelley E Overbeek
P2860
P356
10.2165/11537540-000000000-00000
P577
2011-01-01T00:00:00Z
P6179
1007198815